← Back to all signals
RESEARCH PAPER ANALYSIS

Neuroprotective Role of DING Protein in Normal Aging and Alzheimer's Disease.

The paper reports that DING, a phosphatase found in human brain and derived from St. John's wort, reduces Tau phosphorylation and increases neuronal survival in PC12 cells and correlates with lower phospho‑Tau in a small postmortem human cohort.

PMID42016909
JournalArchives of internal medicine research
Publication Date2026-01-01
Ingested2026-04-28 08:58 PM
EXECUTIVE SUMMARY

What the AI sees

The paper reports that DING, a phosphatase found in human brain and derived from St. John's wort, reduces Tau phosphorylation and increases neuronal survival in PC12 cells and correlates with lower phospho‑Tau in a small postmortem human cohort.

WHY IT MATTERS

Research significance

DING's neuroprotective, Tau‑dephosphorylating activity points to a potentially broad neuroprotective mechanism that could be explored for Parkinson's-related neurodegeneration, but the evidence is limited (small human sample, in vitro models) and it lacks direct data on alpha‑synuclein,…

ABSTRACT

Source abstract

INTRODUCTION: Previously, we showed that the phosphatase DING extracted from St. John's wort (p38SJ) is neuroprotective against EtOH-mediated toxicity in rat and human fetal neurons in vitro. Now, we assess the role of human DING in Alzheimer's disease (AD). DING (p38SJ/p38hu), a member of the DING family of proteins, has been shown to be neuroprotective against cellular stress injury induced by alcohol, HIV-1, and in cancer cells. DING has demonstrated phosphatase activity on MAPK substrates, but its effect on Tau phosphorylation, which is involved in AD, has not yet been explored. METHODS: Expression of DING protein levels was studied in human postmortem brain using histochemistry and quantitative western blot with ANOVA. Five patients with dementia, of whom 3 had AD neuropathology, a fourth had AD/Parkinson complex, and one had cerebrovascular dementia, were compared with 5 non-dementia controls. RESULTS: DING was present in the neuronal cell bodies and processes of both normal and AD-affected human brain tissue. DING demonstrated phosphatase activity in PC12 cells (a cell line derived from rat pheochromocytoma) and inhibited Tau phosphorylation in these cells and in human brain tissue (both normal and AD). Increasing DING by transduction and overexpression in PC12 cells was associated with increased cell survival. In human brains (age=72-92 years), levels of endogenously expressed 38 kDa DING protein correlated positively with Tau dephosphorylation. CONCLUSIONS: Excess Tau phosphorylation leads to the formation of neurofibrillary tangles in neurons, a hallmark of neurodegeneration in Alzheimer's disease. DING inhibits Tau phosphorylation and increases cell viability in non-proliferating neuronal cells overexpressing Tau, while reducing the viability of proliferating cells. Thus, DING may be neuroprotective in AD.

SUPPORTING PAPER SET

32 more papers to review

Ranked by current scoring engine
1 The cGAS-STING-Glymphatic-gut Axis in Parkinson's disease: A proposed self-amplifying triad of Neuroinflammation and therapeutic opportunity. International immunopharmacology 91.0 2 Immunosenescence and Inflammaging as Drivers of Neurodegeneration: Cellular Mechanisms, Neuroimmune Crosstalk, and Therapeutic Implications. Cells 91.0 3 Flavonoids improve neurotransmitters for Parkinson's treatment: mechanism and therapeutic potential. Frontiers in pharmacology 88.0 4 Alpha-Lipoic Acid and Biotin in Neurodegenerative Diseases: Convergent Mechanistic Insights from Preclinical Models to Clinical Perspectives. Neurology international 78.0 5 The Gut Microbiota in Parkinson's Disease: Mechanistic Insights into Microbial-Host Interactions. Microorganisms 85.0 6 Linking inflammation, metabolic dysfunction, and neurodegeneration: a comprehensive review of TLR2 pathways in type 2 diabetes. Frontiers in clinical diabetes and healthcare 80.0 7 Neuroprotective effects of GLP-2 and a GLP-2/GIP dual receptor agonist in an MPTP-induced mouse model of Parkinson's disease. Peptides 86.0 8 TNF alpha unmasks enteric malate aspartate shuttle dysfunction bridging Parkinson disease and intestinal inflammation. Nature communications 91.5 9 Lipid Metabolism and Neurodegeneration: Mechanistic Insights and Therapeutic Targets. Ageing research reviews 82.0 10 Shared functional microbiome signatures in Parkinson's disease and constipation predominate irritable bowel syndrome despite taxonomic divergence. Brain, behavior, & immunity - health 80.0 11 Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases. ChemMedChem 74.0 12 Biomimicking neuromelanin reverses the gait deficits and dopaminergic neuronal loss in the Parkinson's disease. Colloids and surfaces. B, Biointerfaces 86.0 13 Neuroprotective roles of klotho: Molecular pathways and therapeutic implications for cognitive health in neurological and psychiatric diseases. Experimental physiology 84.0 14 Flavonoid Rutin Reduces Intestinal Inflammation in an Experimental Model of Parkinson's Disease. Neurotoxicity research 70.0 15 Nanostructured Lipid Carriers Enhance Brain Delivery and Antioxidant Efficacy of a Small-Molecule MAO B Inhibitor for Neurodegenerative Disease Therapy. Molecular pharmaceutics 78.0 16 Pathophysiological Role of the Gut Brain Axis in Parkinson's Disease: From Microbial Metabolites and Intestinal Permeability to Central Neuroinflammation. Current neurovascular research 86.0 17 Parkinson's Disease: From Metabolism to Genetics-A Comprehensive Review. Current issues in molecular biology 86.0 18 Navigating the cholesterol maze: Key insights on use of statins in neurodegenerative disorders. Neuroprotection (Chichester, England) 76.0 19 Integrative network pharmacology delineates dual GPCR and non-GPCR mechanisms of blended and individual Taikong Blue lavender and Pingyin rose essential oils in neurodegenerative and psychiatric disorders. Computers in biology and medicine 65.0 20 Models of neuroprotection in Parkinson's disease: Exploring cellular, molecular, and microenvironmental targets. Experimental neurology 78.0 21 Hyaluronic acid: emerging roles and biomaterial innovations in Alzheimer's and Parkinson's disease therapy. Frontiers in pharmacology 75.2 22 Molecular mechanisms underlying Parkinson's disease and role of phytochemicals, α-synuclein, sirtuins, and incretin mimetics in potential therapy. Frontiers in pharmacology 75.0 23 Lipid droplets in neurodegenerative diseases: pathological drivers and therapeutic vulnerabilities. Cell death discovery 82.0 24 Brain-gut-microbiota axis: a review on the bidirectional regulatory mechanisms between gut microbiota and brain and their disease interactions. Frontiers in microbiology 74.0 25 Long non-coding RNAs in neurodegenerative diseases - Molecular mechanisms, liquid biopsy biomarkers, and therapeutic targets: A review. Biomolecules & biomedicine 84.0 26 Neurosyphilis and Parkinsonism: Overlapping Pathophysiology and Emerging Therapeutic Insights. Current neurovascular research 76.0 27 Molecular biochemistry of soluble epoxide hydrolase in lipid mediator pathways and neuroinflammatory responses. The Journal of steroid biochemistry and molecular biology 82.0 28 Multifaceted role of CNPY2 beyond ER stress: Disease implications and therapeutic potential. Cell stress 83.3 29 Neuroprotective Role of Exercise-based Physiotherapy Combined with Pharmacological Agents in Parkinson's Disease. Central nervous system agents in medicinal chemistry 64.0 30 Distinct metabolomic and proteomic signatures in Parkinson's disease patients with REM sleep behavior disorder. Signal transduction and targeted therapy 84.0 31 HMGB1-mediated neuroinflammation: molecular mechanisms and emerging therapeutic approaches. Inflammopharmacology 78.0 32 Beyond acid-base dyshomeostasis: Dynamic instability of neuronal lysosomal pH as a pathogenic mechanism and therapeutic target in neurological diseases. Biochemical pharmacology 88.0
Neurocompute Parkinson’s Narrative Velocity Infographic
NEUROCOMPUTE VISUAL SYSTEM

Open the Narrative Velocity Map

Explore the full Parkinson’s research intelligence diagram.

Expand Intelligence View →
Full Neurocompute Infographic